As an m6A reader, IGF2BP1 enhances RNA stability by recognizing m6A modifications.[31] IGF2BP1 is highly expressed and induces drug resistance in colorectal cancer,[32] ovarian cancer,[33] and osteosarcoma[34] and contributes to oxaliplatin resistance by enhancing stemness in gastric cancer.[35] Herein, we found that IGF2BP1 expression is upregulated in PDAC and positively correlates with GEM resistance. Here, IGF2BP1 is linked to ovarian carcinoma.